Thermo Fisher Scientific has been racking up deals over the past few years to boost its diagnostics capabilities. Its latest target? Sequencing giant Illumina, to the tune of $30 billion.
Thermo Fisher has put forward a $30 billion all-stock offer, according to an unnamed source with knowledge of the matter, StreetInsider reported. Illumina, which notched $600 million in Q2 revenues, has a $25 billion market cap, and gained as much as 8% on news of the acquisition proposal. Analysts are critical of the prospects of the deal.
In April 2012, Illumina successfully fought off a $6.7 billion hostile takeover attempt by Roche ($RHHBY), which grew from the initial $5.7 billion offer the Big Pharma proposed in January. Illumina and its shareholders rejected the deal because the price was too low.
Thermo Fisher, with a $61 billion market cap, reels in about $17 billion in revenues annually. It has made a string of acquisitions in the last few years and filed a Form S-3 in March, registering a mixed securities shelf for “general corporate purposes” that “may include the acquisition of companies and businesses.”
Most recently, Thermo Fisher picked up FEI and its electron microscopy technology in a $4.2 billion transaction, while in March, it closed its $1.3 billion purchase of Affymetrix, expanding its drug research and genetic analysis capabilities in the process. Prior to that, the company acquired bioprocessing firm Advanced Scientifics for $300 million in 2015 and Life Technologies for $13.6 billion in 2014, adding it to its Life Sciences Solutions Group.
By Amirah Al Idrus
Source: Fierce Biotech
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.